Form 603

Corporations Act 2001 Section 671B

Notice of initial substantial holder

2. Details of voting power	
The holder became a substantial holder on	04/06/2020
ACN/ ARSN (if applicable)	
1. Details of substantial holder (1) Name	L1 Capital Global Opportunites Master Fund
ACN/ ARSN	609 406 911
To Company Name/ Scheme	CRESO PHARMA LIMITED

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4) Number of sec		Number of securities	Person's votes (5)	Voting power (6)
FPO 17.968.888		17,968,888	6.44%	

*Based on issued capital of 279,140,235 shares

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
See Schedule 1		

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered Holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
See Schedule 1			

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant	Date of	Consideration (9)			
interest	acquisition	Cash	Non-cash	Class and number of securities	

603 page 2/2 15 July 2001

6. Associates

Name and ACN/ ARSN (if applicable)	Nature of association
N/A	

7. Addresses

(9)

was acquired.

The addresses of persons named in this form are as follows:

Name	Address
L1 Capital Global Opportunites Master Fund	161a Shedden Road, One Artillery Court, Grand Cayman, Cayman Islands

Signature					
	Print name	David Feldman	Capacity	Director	
	Sign here	ML	Date	9/06/2020	
			DIRECTIONS		
(1)	trust), the names could	be included in an annexure to the form	n. If the relevant interests of a group	tion and its related corporations, or the manager and trustee or of persons are essentially similar, they may be referred to thro es of members is clearly set out in paragraph 7 of the form.	. ,
(2)	See the definition of "as	ssociate" in section 9 of the Corporatio	ns Act 2001.		
(3)	See the definition of "re	elevant interest" in sections 608 and 67	71B(7) of the Corporations Act 2001.		
(4)	The voting shares of a	company constitute one class unless o	divided into separate classes.		
(5)	The total number of vote	es attached to all the voting shares in	the company or voting interests in th	e scheme (if any) that the person or an associate has a releva	ant
(6)	The person's votes divid	ided by the total votes in the body corp	orate or scheme multiplied by 100.		
(7)	settii		ment, and a statement by the persor	vas acquired. If subsection 671B(4) applies, a copy of any doo n giving full and accurate details of any contract, scheme or ar tract, scheme or arrangement; and	
	(b)				
				r influence the exercise of, the voting powers or disposal of th securities to which the qualification applies).	ie
	See the definition of "rel	elevant agreement" in section 9 of the 0	Corporations Act 2001.		
(8)	If the substantial holder	is unable to determine the identity of t	the person (eg. if the relevant interes	st arises because of an option) write "unknown".	

Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest

Schedule 1 - L1 Capital Global Opportunities Master Fund becoming a substantial holder in CRESO PHARMA LIMITED **Details of relevant interests**

Holder of relevant interest	Nature of relevant interest	Class and number of securities	
	Power to (or to control) exercise vote and/or dispose of the securities as discretionary investment managers or advisers of superannuation funds, pooled superannuation trusts, managed investment schemes and investment management agreements.		17,968,888

Details of present registered holders

Holder of relevant interest	Registered holder of securities	Persons entitled to be a registered holder	Class and number of securities
L1 Capital Global Opportunities Master Fund	Credit Suisse	Credit Suisse	17,968,888

17,968,888